A Randomized, Multicenter, Double-blind, Placebo-controlled comparison of chemotherapy08/29/2012 - 02/28/2023 (PI)
Genentech, Inc.
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer03/13/2014 - 03/12/2019 (PI)
Celldex Therapeutics, Inc.
A Randomized, 3 Arm, Multi-Center, Phase III Study to Evaluate the Efficacy and the Safety or T-DM1 Combined with Pertuzumab or T-DM1 Combined with Pertuzumab-Placebo (Blinded for Pertuzumab), versus11/23/2010 - 05/11/2016 (PI)
Genentech, Inc.
A RANDOMIZED, MULTICENTER, PHASE III OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMABMCC-DM1 VS. CAPECITABINE + LAPATINIB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC02/23/2009 - 11/21/2012 (PI)
Genentech, Inc.
A Phase III Randomized Double Blind Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Vs Placebo + Trastuzumab+ Docetaxel in Previously02/23/2009 - 03/31/2012 (PI)
Genentech, Inc.
Phase II Multi-Center, Randomized, Blinded Placebo-Controlled Trial of Carboplatin & Gemcitabine plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallo01/14/2008 - 01/13/2012 (PI)
Genentech, Inc.
A Phase III, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG or Placebo in Women With Recurrent Partiality Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or12/02/2010 - 11/30/2011 (PI)
Amgen, Inc.
CA023: A Randomized Phase II Trial of Weekly vs Every 2 Wk vs Every 3 Wk Administration of ABI-007 in Combination of Bevacizumab in Women with Metastatic Breast01/25/2007 - 09/23/2011 (PI)
Abraxis Bioscience, Inc.
Phase 3, Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Alfimeprase in Subjects with Occluded Central Venous Access Devices09/27/2006 - 09/26/2008 (PI)
Nuvelo, Inc.
A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes and Refractory to the Most Recent Chemother08/30/2007 - 08/29/2008 (PI)
Eisai Medical Research Institute, Inc.
Showing 10 of 21 results.
Show All Results
Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of AG-013736 in Combination With Docetaxel Alone in Patients With Metastatic Breast Cancer Preceded by a Phase 1 Evaluation of the Combination
09/24/2004 - 09/23/2007 (PI)
Pfizer, Inc.
A Phase II Multicenter, Randomized, Double-Blind, Placebo-controlled, Dose-ranging, Parallel Group Study of the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered as 50mg, 100mg, and 150mg Oral Tablets in Combina
01/06/2005 - 01/05/2007 (PI)
GlaxoSmithKline, Inc.
Phase II Study of Capecitabine in Combination with Intravenous Docetaxel in Patients with Locally Advanced and/or Metastatic Breast Cancer
08/01/2003 - 12/31/2005 (PI)
Hoffmann-La Roche Inc (Foreign)
A Phase III, Randomized, Placebo-Controlled, Double-Blind, Study of Oral CCI-779 Administered in Combination with Ltrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women with Locally Advanced Metastatic Breast Cancer
11/12/2004 - 11/11/2005 (PI)
Wyeth-Ayerst Pharmaceuticals Inc
A Phase III Randomized Study of TLK286 Versus Doxil/Caelyx or Hycamtin as Third-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer
06/21/2004 - 06/20/2005 (PI)
Telik, Inc.
Phase II Trial of Paclitaxel or Docetaxel and Herceptin Administered Every Three Weeks
03/01/2002 - 02/28/2004 (PI)
Genentech, Inc.
Actimmune in Combination with Chemotherapy for First-line Therapy of Advanced Ovarian or Primary Peritoneal Carcinoma
02/01/2002 - 01/31/2004 (PI)
InterMune, Inc.
A Multicenter, Open Label, Phase III, Randomized, Active Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination with Capecitabine Chemotherapy, in Subjects with Previously Treated Metastatic Bre
01/09/2001 - 12/31/2003 (PI)
Genentech, Inc.
Multicenter, Open Label, Randomized Study of Three Schedules of Weekly Taxol Induction Therapy Followed by Weekly Taxol Maintenance Therapy in Metastatic Breast Cancer Patients
04/03/2000 - 12/31/2002 (Co-PI)
Theradex (behalf of Bristol-Myers Squibb)
A Controlled Randomized Multicenter Phase III Open Label Study of ABI-007 (a Cremophor Free Protein Stabilized Nanoparticle Paclitaxel) and Taxol in Patients with Metastatic Breast Cancer
11/15/2001 - 11/15/2002 (PI)
Health Decisions Inc Amer BioScience Inc
An Open Label, Multicenter, Randomized, Phase II Study of Oral Topotecan Daily x 5 Days vs. Oral Topotecan 5 Days On, 2 Days Off for 3 Weeks for Second Line Treatment in Patients with Recurrent, Locally Advanced or Metastatic Cervical Cancer
08/14/2000 - 12/31/2001 (PI)
SmithKline Beecham
Olaparib Monotherapy vs. Chemotherapy12/19/2014 - 03/31/2019 (PI)
Astrazeneca Pharmaceuticals
LEE01101/19/2016 - 12/31/2018 (PI)
Novartis Pharma Corp
ACRIN 6691 : Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse11/01/2012 - 11/01/2013 (PI)
Amer College of Radiology NIH-NCI